Research at the Dana Center focuses on national and international public health prevention of blinding eye disease. Some major studies include:
Recognition of the importance of adequate vitamin A for the sight and survival of young children;
Demonstration of the value of invermectin as the first safe drug for the treatment and control of onchocerciasis (river blindness);
Elucidation of the mechanisms underlying blinding trachoma and recognition that in some communities simple face-washing may provide the most practical means of prevention;
Development and application of new techniques for glaucoma screening including targeting groups at particularly high risk of disease; and
Community-based trials in Tanzania.